General Information of Drug (ID: DMPH1RK)

Drug Name
Alferminogene tadenovec Drug Info
Synonyms Generx (TN)
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Phase 3 [1]
Heart disease BA41-BA42 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMPH1RK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pentosan Polysulfate DM2HRKE Interstitial cystitis GC00.3 Approved [3]
Ad5FGF-4 DMVLWG7 Angina pectoris BA40 Phase 3 [4]
Generx DM1WMOK Angina pectoris BA40 Phase 3 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-4 (FGF4) TTCEKVZ FGF4_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N.
5 Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46.